PUBLICATION

Gene-specific differential response to anti-apoptotic therapies in zebrafish models of ocular coloboma

Authors
Gregory-Evans, C.Y., Moosajee, M., Shan, X., and Gregory-Evans, K.
ID
ZDB-PUB-110628-37
Date
2011
Source
Molecular Vision   17: 1473-1484 (Journal)
Registered Authors
Keywords
none
MeSH Terms
  • Amino Acid Chloromethyl Ketones/pharmacology
  • Animals
  • Blotting, Western
  • Caspase 3/genetics
  • Caspase 3/metabolism
  • Cell Death/drug effects
  • Cell Death/genetics*
  • Coloboma*/embryology
  • Coloboma*/genetics
  • Coloboma*/metabolism
  • Coloboma*/pathology
  • Curcumin/pharmacology*
  • Cytochromes c/analysis
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Embryo, Nonmammalian
  • Eye/embryology
  • Eye/metabolism*
  • Eye/pathology
  • Genetic Variation
  • In Situ Nick-End Labeling
  • Longevity/drug effects
  • Mitochondria/drug effects
  • Mitochondria/metabolism
  • Mutation
  • Phenotype
  • Zebrafish/embryology
  • Zebrafish/genetics*
  • Zebrafish/metabolism
  • Zebrafish Proteins/genetics
  • Zebrafish Proteins/metabolism
PubMed
21677791
Abstract

PURPOSE:

We recently demonstrated that molecular therapy using aminoglycosides can overcome the underlying genetic defect in two zebrafish models of ocular coloboma and showed abnormal cell death to be a key feature associated with the optic fissure closure defects. In further studies to identify molecular therapies for this common congenital malformation, we now examine the effects of anti-apoptotic compounds in zebrafish models of ocular coloboma in vivo.

METHODS:

Two ocular coloboma zebrafish lines (pax2.1/noi(tu29a) and lamb1/gup(m189)) were exposed to diferuloylmethane (curcumin) or benzyloxycarbonyl-Val-Ala-Asp(Ome)-fluoromethylketone (zVAD-fmk; a pan-caspase inhibitor) for up to 8 days post-fertilization. The effects of these compounds were assessed by morphology, histology, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining and western blot analysis.

RESULTS:

The size of the coloboma in gup zebrafish mutants treated with diferuloylmethane was greatly reduced. In treated mutants a reduction in TUNEL staining and a 67% decrease in activated caspase-3 protein were observed. The release of cytochrome c from the mitochondria into the cytosol was reduced fourfold by in vivo diferuloylmethane treatment, suggesting that the drug was acting to inhibit the intrinsic apoptotic pathway. Inhibition of caspases directly with zVAD-fmk also resulted in a similar reduction in coloboma phenotype. Treatment with either diferuloylmethane or zVAD-fmk resulted in a statistically significant 1.4 fold increase in length of survival of these mutant zebrafish (p<0.001), which normally succumb to the lethal genetic mutation. In contrast, the coloboma phenotype in noi zebrafish mutants did not respond to either diferuloylmethane or zVAD-fmk exposure, even though inhibition of apoptotic cell death was observed by a reduction in TUNEL staining.

CONCLUSIONS:

The differential sensitivity to anti-apoptotic agents in lamb1-deficient and pax2.1-deficient zebrafish models, suggests that apoptotic cell death is not a final common pathway in all ocular coloboma genotypes. When considering anti-cell death therapies for ocular colobomatous defects attention should be paid to the genotype under investigation.

Genes / Markers
Figures
Show all Figures
Expression
Phenotype
Mutation and Transgenics
Human Disease / Model Data
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping
Errata and Notes